Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SPP1+ Neutrophils Mediate Resistance to lmmune Checkpoint Blockade in BAP1-Inactivated Tumors

ABSTRACT: BAP1 inactivation, observed across multiple human cancers, is linked to immune checkpoint blockade (ICB) resistance and adverse clinical outcomes. The mechanisms underlying BAP1-associated ICB sensitivity could provide potential targets to enhance ICB efficacy. Here, we showed that BAP1 inactivation fosters an immunosuppressive tumor microenvironment (TME), marked by increased infiltration of M2-like macrophages and neutrophils. Single-cell transcriptomic analysis revealed an expansion of SPP1+ neutrophils in ICB-treated, BAP1-inactivated tumors. These SPP1+ neutrophils displayed a pro-tumorigenic phenotype and conferred resistance to anti-PD-1 therapy by engaging with cytotoxic T cells via PD-1/PD-L1 signaling. Notably, depletion of neutrophils, but not macrophages, restored sensitivity to ICB in BAP1-inactivated tumors. Mechanistically, BAP1 loss significantly increased CCL2 secretion, driving neutrophil SPP1+ polarization, delaying neutrophil apoptosis, and promoting ICB resistance. This resistance could be significantly mitigated by targeting the CCL2-CCR2 axis. These results underscore the role of BAP1 in modulating the immune landscape and suggest that targeting CCL2-CCR2-mediated neutrophil polarization may overcome ICB resistance in BAP1-inactivated tumors.

ORGANISM(S): Mus musculus

PROVIDER: GSE284219 | GEO | 2025/09/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

SPP1+ Neutrophils Mediate Resistance to lmmune Checkpoint Blockade in BAP1-Inactivated Tumors

Project description:SPP1+ Neutrophils Mediate Resistance to lmmune Checkpoint Blockade in BAP1-Inactivated Tumors

| PRJNA1198010 | ENA

Immunosubtyping of breast cancer reveals distinct myeloid cell biology and immunotherapy resistance mechanisms

Project description:Cancer-induced immune responses affect tumor progression and therapeutic response. In multiple murine models and clinical datasets, we identified large variations of neutrophils and macrophages, which define “immune subtypes” of triple negative breast cancer (TNBC) including neutrophil-enriched (NES) and macrophage-enriched subtypes (MES). Different tumor-intrinsic pathways and mutual regulation between macrophages/monocytes and neutrophils contribute to the development of dichotomous myeloid compartment. MES contains predominantly macrophages that are CCR2-dependent and exhibit variable responses to immune checkpoint blockade (ICB). NES exhibits systemic and local accumulation of immunosuppressive neutrophils (or granulocytic myeloid-derived suppressor cells (gMDSCs), is resistant to ICB, and contains a minority of macrophages that appear to be unaffected by CCR2 knockout. A MES-to-NES conversion mediated acquired ICB resistance of initially sensitive MES models. Our results demonstrate diverse myeloid cell frequencies, functionality, and potential roles in immunotherapies, and highlight the need to better understand the inter-patient heterogeneity of the myeloid compartment.

2019-06-30 | GSE104765 | GEO

TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer

Project description:Triple-negative breast cancer (TNBC) is the most aggressive form of BC and despite improvements in neoadjuvant treatment with immune checkpoint blockade (ICB) targeting PD-1, response rates vary, and patients relapse with metastatic disease. Using human samples and mouse models, we show that myeloid cells, particularly monocytes, increase in aggressive TNBC draining lymph nodes (TDLN) showing T-cell suppressive capacity via PD-L1 and iNOS. Tumor-induced TLR4 ligands reprogrammed TDLN fibroblastic reticular cells (FRCs) through TLR4 activation to induce the recruitment of monocytes via CCL2 and CCL7 in vascularized and T-cell areas. Indeed, monocytes expressing the receptor of CCL2/7 CCR2 home to and colocalize with FRC-rich niches. The local inhibition of this recruitment axis at the TDLN site, either through CCR2 or TLR4 inhibition, in combination with PD-1 blocking, resulted in reduced LN and distant lung metastasis in mouse models. A subset of TNBC patients with worse survival was stratified using TLR4 ligands, including TNC, S100A9, and FN1. Our results thus demonstrate a novel mechanism through which metastatic TNBC tumors reprogram the TDLN-niche to facilitate PD-L1-mediated immune evasion that precedes and drives metastasis. We thereby provide an opportunity to improve the efficacy of ICB in TNBC patients and to use the TDLN or our primary tumor signature as predictive biomarkers.

2025-09-17 | GSE267535 | GEO

TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer

2025-09-17 | GSE267534 | GEO

TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer

2025-09-17 | GSE267533 | GEO

Transcriptome analysis of CD16/CD62L neutrophil subsets during human experimental endotoxemia

Project description:During systemic inflammation, different neutrophil subsets are mobilized to the blood circulation. These neutrophil subsets can be distinguished from normal circulating neutrophils (CD16bright/CD62Lbright) based on either an immature CD16dim/CD62Lbright or a CD16bright/CD62Ldim phenotype. Interestingly, the latter neutrophil subset is known to suppress lymphocyte proliferation ex vivo, but the underlying mechanism is largely unknown. We performed transcriptome analysis on the different neutrophil subsets to identify changes that are relevant for their functions. Neutrophil subsets were isolated by FACS sorting from the blood of healthy volunteers who were administered a single dose of lipopolysaccharide (LPS). The transcriptome was determined by microarray. The mobilized neutrophil subsets were characterized by specific transcriptome profiles reflecting their phase in neutrophil lifespan. Interestingly, the CD16bright/CD62Ldim suppressive neutrophils showed an interferon-induced transcriptome profile. This was confirmed by stimulation of peripheral neutrophils with IFNgamma. These cells acquired the capacity to suppress lymphocyte proliferation through the expression of programmed death ligand 1 (PD-L1). These data demonstrate that the suppressive phenotype of the neutrophil subset is induced by IFNgamma. Specific stimulation of neutrophils might have a pivotal role in regulating lymphocyte-mediated inflammation and autoimmune disease. After LPS infusion, blood was taken at t=0 and t=4 hours. Neutrophils were FACS sorted based on CD16 and CD62L expression. Gene expression of neutrophil subsets was assessed relative to t=0 as control.

2013-05-01 | E-GEOD-42358 | biostudies-arrayexpress

Phosphoproteomic Characterization of Signaling Networks Resulting from Activation of Chemokine Receptor CCR2

Project description:Leukocyte recruitment, a universal feature of tissue inflammation, is regulated by the interactions of chemokines with their G protein-coupled receptors. Activation of CC chemokine receptor 2 (CCR2) by its cognate chemokine ligands, including CCL2, plays a central role in recruitment of monocytes in several inflammatory diseases. In this study, we used phosphoproteomics to enable unbiased characterization of the signaling network resulting from CCL2 activation of CCR2. Using data-independent acquisition (DIA) mass spectrometry, both the proteome and phosphoproteome were quantified for FlpIn-HEK293T cells stably expressing CCR2, at six time points after activation with CCL2, in comparison with untreated cells. Differential expression analysis identified 699 significantly regulated phosphorylation sites located on 441 proteins. As expected, many of these proteins participate in canonical signal transduction pathways and the regulation of actin cytoskeleton dynamics, including numerous guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). In addition, we identified regulated phosphorylation sites in numerous proteins that exert functions in the nucleus, including several constituents of the nuclear pore complex. This study provides an unprecedented level of detail about CCR2 signalling and identifies potential novel targets for regulation of CCR2 function.

2020-04-08 | PXD015845 | Pride

Single-Cell Profiling of Neutrophil Gene Expression in the Mouse Colon following TNBS-induced Colitis

Project description:Neutrophil infiltration is hallmark of chemically induced colitis and inflammatory bowel disease (IBD). We used single-cell RNA sequencing to analyze heterogenity in infiltrated colonic neutrophil population in presence and absence of microbiota, or when DUOX2 in inactivated in neutrophils.

2025-05-22 | GSE290398 | GEO

Chil3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases [scRNA-seq]

Project description:Bone metastases remain incurable and respond poorly to immune checkpoint blockade (ICB) therapy. The impact of neutrophil maturation in cancer remains largely unknown, especially in refractory tumors including bone metastases. Here, we observed the predominance of immature neutrophils in the bone metastasis microenvironment of both mouse models and cancer patients. DKK1 induces the immature-like functional state in neutrophils, which exert robust immunosuppressive capabilities to inhibit anti-tumor response of CD8+ T cells. Mechanistically, driven by the DKK1-CKAP4-STAT6 signaling, Chil3 expression is identified and required for the immune suppression mediated by immature neutrophils in bone metastases. Moreover, using multiple syngeneic and human immune system (HIS) mouse models, we found that DKK1 blockade efficiently allows neutrophil maturation to improve the immune microenvironment, controls tumor progression, and enhances ICB therapy response in bone metastases. Thus, our findings uncover an essential role for immature neutrophils in cancer, especially in bone metastases, and propose a potential strategy modulating neutrophils to improve cancer immunotherapy.

2025-06-01 | GSE295533 | GEO

Chil3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases [RNA-Seq]

2025-06-01 | GSE295537 | GEO